Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06698250 |
| Title | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) (ZENOBIA) |
| Acronym | ZENOBIA |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Anwaar Saeed |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UPMC Hillman Cancer Center | RECRUITING | Pittsburgh | Pennsylvania | 15232 | United States | Details |
| Houston Methodist Neal Cancer Center | NOT_YET_RECRUITING | Houston | Texas | 77030 | United States | Details |
| Mays Cancer Center, UT Health San Antonio | NOT_YET_RECRUITING | San Antonio | Texas | 78229 | United States | Details |